Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Conditions
Keywords
Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Brief summary
This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and lung tumors.
Detailed description
This is a seamless phase I/II trial with two separate disease groups/cohorts (centrally located lung tumors and locally advanced/unresectable pancreatic ductal adenocarcinoma-LAPC). The Phase I part is determining for each disease group a safe dose-level that will be evaluated in the Phase II component of the study. The phase II part of the study is a randomized controlled trial that tests, for each disease group, the treatment efficacy of stereotactic body radiation therapy (SBRT) in combination with AGuIX gadolinium-chelated polysiloxane based nanoparticles compared to treatment with stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) alone The U.S. Food and Drug Administration (FDA) has not approved Activation and Guidance of Irradiation X (AGuIX) as a treatment for any disease. AGuIX is a gadolinium-based nanoparticle, gadolinium is the drug used for an MR with contrast. It is believed that the AGuIX may help the radiation received work better by making a tumor more sensitive to the radiation and allowing doctors to see the tumor more clearly. AGuIX has been tested in one previous study with humans. It was found that AGuIX did make tumor cells more sensitive to radiation therapy. The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. Participants will receive study treatment for 5 treatment days and will be followed for a year after your treatment ends. It is expected that about 100 people will take part in this research study.
Interventions
DRUGAGuIX
Injected gadolinium-based nanoparticles
RADIATIONRadiotherapy
Stereotactic magnetic resonance-guided adaptive radiation therapy
Sponsors
NH TherAguix SAS
Dana-Farber Cancer Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients should have clinical, radiographical, cytological, or histological confirmation of NSCLC or lung or nodal metastases from another primary cancer defined as within or touching the zone of the proximal bronchial tree, defined as a volume 2 cm in all directions around the trachea and proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus right and left lower lobe bronchi). Tumors that are immediately adjacent (\<1 cm) to mediastinal or pericardial pleura or other radiation-sensitive organs such as the esophagus and brachial plexus also are considered central tumors and are eligible for this protocol. OR Histologically or cytologically confirmed pancreatic ductal adenocarcinoma of the pancreatic head, body or tail. * Participants must have measurable disease, defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. See Section 11 for the evaluation of measurable disease. Eligible NSCLC patients must have no evidence of nodal involvement (N0), and disease has to be determined unresectable by a thoracic oncologist or the patient is medically inoperable. * Locally advanced, unresectable pancreatic cancer as determined by a pancreaticobiliary surgeon as part of a multidisciplinary discussion at the investigative site, including multi-phasic CT demonstrating tumor abutment of the SMA or celiac axis, SMV or PV involvement which is not resectable without vascular reconstruction. * Completion of at least 3 months of standard induction chemotherapy for LAPC, which should consist of either FOLFIRINOX, gemcitabine and nab-paclitaxel, or another standard combination of induction chemotherapy agent, with a washout period no longer than 10 weeks prior to first dose of study drug. * No evidence of distant metastasis. * Pancreatic or central NSCLC size ≤ 5cm. * Age 18 years or older. * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). * Ability to understand and follow the breathing instructions involved in the respiratory gating procedure. * Participants must have normal organ and marrow function as defined below: * absolute neutrophil count ≥1,500/mcL * platelets ≥100,000/mcL * total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal * creatinine within normal institutional limits OR * Creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. * The effects of AGuIX on the developing human fetus are unknown. For this reason, as well as the known teratogenic effects of radiation, women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Participants who have had prior radiation therapy to the chest or abdomen that would overlap with the current treatment field. * Participants who are receiving any other investigational agents. * Participants with known metastatic disease. * History of allergic reactions attributed to gadolinium-based IV contrast. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because AGuIX is contrast agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AGuIX, breastfeeding should be discontinued if the mother is treated with AGuIX. * Severe claustrophobia or anxiety. * Known HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AGuIX. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated. * Active duodenal or gastric ulcer disease or evidence of tumor invasion of the bowel or stomach based on endoscopy. * Presence of a duodenal stent. * Unable to undergo magnetic resonance imaging (MRI) due to any of the following: 1. Presence of MRI-incompatible metal material or devices in the human body 2. MRI-incompatible Pacemaker or defibrillator 3. Insulin pump 4. Aneurysm clip 5. Artificial heart valve 6. Cochlear implant 7. Shrapnel or gunshot injury 8. Cataract surgery with implant unsafe for MRI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (MTD) Phase 1 | 3 months | Evaluated by the occurrence of Dose Limiting Toxicity (DLT) over the duration of the study using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 |
| Compare Local Control at 12 months of Maximum tolerated dose MTD - Phase 2 | 12 months | Evaluate SMART + AGuIX local control at 12 months compared to SMART alone. Local control at 12 months is defined as the treated tumor is equal to or less than the tumor volume at start of SMART. Progression would be defined per RECIST criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serious Adverse Events at 90 Days | 90 days | NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be used. |
| Serious Adverse Events at 12 months | 12 months | NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be used. |
| Tumor Changes | Enrollment through study completion, an average of 1 year | Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. |
| Compare disease-specific survival | Enrollment through study completion, an average of 1 year | Bayesian hierarchical two-sample test for binary outcomes |
| Progression-free survival (PFS) at Maximum tolerated dose (MTD) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Assessed by RECIST criteria |
| Compare overall survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Bayesian hierarchical two-sample test for binary outcomes |
| Quality of Life (QoL)-Performance Status utilizing PROMIS Physical and Mental Health batteries | Baseline through study completion, an average of 1 year | Described using descriptive statistics and longitudinal analyses |
| Quality of Life (QoL)-Completion of Daily Activities utilizing PROMIS Physical and Mental Health batteries | Baseline through study completion, an average of 1 year | Described using descriptive statistics and longitudinal analyses |
| compare R0 resection rate | Enrollment through study completion, an average of 1 year | Bayesian hierarchical two-sample test for binary outcomes |
| Overall Response Rate (ORR) at Maximum tolerated dose (MTD) | Enrollment through study completion, an average of 1 year | Assessed by RECIST criteria |
Countries
United States
Contacts
Primary ContactJonathan Leeman, MD
Outcome results
None listed